CBT-009 not checked

Cloudbreak Therapeutics, LLC

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
3 active
6 in total · 5 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.”In the company’s words, NCT05372991 on ClinicalTrials.gov
Tested for
Myopia, Progressive
Main trialPhase 1/2
“This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers. CBT-009 has the active ingredient of atropine, which at low doses, has shown to be effective in slowing down myopic deterioration. Current atropine products are prone to degradation once the container is open to the air. ADS Pharmaceutical has developed a novel atropine formulation.”In the company’s words, NCT05372991 on ClinicalTrials.gov
Other names
Atropine

Other drugs for Myopia, Progressive

All 3 drugs for Myopia, Progressive

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 1/2Completed 18 Jan 2023 Safety, Tolerability and Pharmacodynamics Evaluation of CBT-009 Eye Drop
Phase 3Authorised not given Low-dose AtropIne for Myopia control in children
Phase 4Ended not given Postmarketing Parallel Randomized Clinical Trial to Determine the Efficacy and Safety of Atropine and DIMS Lenses in the Control of Myopia in a Pediatric Population
Phase 3Authorised not given A phase III, randomized, double-masked, placebocontrolled, parallel-group, multicenter study of the safety and efficacy of OT-101 (Atropine Sulfate 0.01%) in treating the progression of myopia in pediatric subjects
Phase 4Authorised not given Investigator led, double-masked, multicentre, randomized clinical trial for the comparison of atropine 0.5% versus atropine 0.05% eye drops for the prevention of myopia progression in Dutch children
Phase 2Ended not given A randomized, double-blind, placebo-controlled dose-finding study of 0.05%, 0.025%, 0.01% and 0.005% atropine eye drops to inhibit myopia progression in children in a European population
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow CBT-009

Following is part of Solo: you see every change to CBT-009 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in